Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295093> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4286295093 endingPage "e16126" @default.
- W4286295093 startingPage "e16126" @default.
- W4286295093 abstract "e16126 Background: Hepatocellular carcinoma (HCC) is the most common liver malignancy associated with poor prognosis. With the rapid development of systematic therapy for liver cancer, immunotherapy has been widely used in therapy of liver cancer. Hyperprogression of tumor is a phenomenon of accelerated tumor growth, which occurs in patients with liver cancer and other solid tumors receiving systematic treatment, and is mainly related to immunotherapy hyperprogression genes. However, it is still unclear about the genes of immune hyperprogression in HCC patients. Therefore, we studied the molecular characteristics of HCC patients, including the genes related to immunotherapy hyperprogression. Methods: From June 2019 to August 2021, 102 patients with HCC were inculded in this study. Matched tumor/normal DNA from HCC patients (N = 102) were analyzed by whole exome sequencing (WES) or Acornmed panel with 808 cancer-related genes. Results: Overall, 86.3% (88/102) patients exhibited genetic alterations. TP53 (50%), TERT (23%), CTNNB1 (18%) and KMT2C (14%) were the most commonly mutated genes in HCC. In addition, 8.9% patinets harbored at least one immunotherapy hyperprogressive gene mutations, including CCND1 (7%), FGF19 (6%), FGF3 (5%), FGF4 (5%) and MDM4 (2%). In addition, CCND1 and FGF19 were frequently mutated genes in patients with liver cancer, ranking ninth and tenth, respectively. Compared with the TCGA data, there was no significant difference in immunotherapy hyperprogressive genes (25% vs 32.3%, p = 0.18). Interesting, CCND1, FGF19, FGF3 and FGF4 mutations occurred simultaneously in most patients and were mutually exclusive with MDM4 (p = 0.057). Conclusions: This study contributes to understand the molecular characteristics of patients with HCC, which will be useful to guide immunotherapy and promote the clinical management in this population. Furthermore, the study suggested that both Chinese and Western populations should pay attention to immunotherapy hyperprogression genes in immunotherapy selection." @default.
- W4286295093 created "2022-07-21" @default.
- W4286295093 creator A5000682982 @default.
- W4286295093 creator A5007209836 @default.
- W4286295093 creator A5016136940 @default.
- W4286295093 creator A5023874610 @default.
- W4286295093 creator A5028458322 @default.
- W4286295093 creator A5052345420 @default.
- W4286295093 creator A5063837322 @default.
- W4286295093 creator A5086404508 @default.
- W4286295093 date "2022-06-01" @default.
- W4286295093 modified "2023-09-27" @default.
- W4286295093 title "Clinical utility of immunotherapy hyperprogressive genes in hepatocellular carcinoma patients." @default.
- W4286295093 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e16126" @default.
- W4286295093 hasPublicationYear "2022" @default.
- W4286295093 type Work @default.
- W4286295093 citedByCount "0" @default.
- W4286295093 crossrefType "journal-article" @default.
- W4286295093 hasAuthorship W4286295093A5000682982 @default.
- W4286295093 hasAuthorship W4286295093A5007209836 @default.
- W4286295093 hasAuthorship W4286295093A5016136940 @default.
- W4286295093 hasAuthorship W4286295093A5023874610 @default.
- W4286295093 hasAuthorship W4286295093A5028458322 @default.
- W4286295093 hasAuthorship W4286295093A5052345420 @default.
- W4286295093 hasAuthorship W4286295093A5063837322 @default.
- W4286295093 hasAuthorship W4286295093A5086404508 @default.
- W4286295093 hasConcept C104317684 @default.
- W4286295093 hasConcept C121608353 @default.
- W4286295093 hasConcept C126322002 @default.
- W4286295093 hasConcept C143998085 @default.
- W4286295093 hasConcept C2776231280 @default.
- W4286295093 hasConcept C2777701055 @default.
- W4286295093 hasConcept C2778019345 @default.
- W4286295093 hasConcept C2779399171 @default.
- W4286295093 hasConcept C502942594 @default.
- W4286295093 hasConcept C54355233 @default.
- W4286295093 hasConcept C71924100 @default.
- W4286295093 hasConcept C86803240 @default.
- W4286295093 hasConceptScore W4286295093C104317684 @default.
- W4286295093 hasConceptScore W4286295093C121608353 @default.
- W4286295093 hasConceptScore W4286295093C126322002 @default.
- W4286295093 hasConceptScore W4286295093C143998085 @default.
- W4286295093 hasConceptScore W4286295093C2776231280 @default.
- W4286295093 hasConceptScore W4286295093C2777701055 @default.
- W4286295093 hasConceptScore W4286295093C2778019345 @default.
- W4286295093 hasConceptScore W4286295093C2779399171 @default.
- W4286295093 hasConceptScore W4286295093C502942594 @default.
- W4286295093 hasConceptScore W4286295093C54355233 @default.
- W4286295093 hasConceptScore W4286295093C71924100 @default.
- W4286295093 hasConceptScore W4286295093C86803240 @default.
- W4286295093 hasIssue "16_suppl" @default.
- W4286295093 hasLocation W42862950931 @default.
- W4286295093 hasOpenAccess W4286295093 @default.
- W4286295093 hasPrimaryLocation W42862950931 @default.
- W4286295093 hasRelatedWork W2078805591 @default.
- W4286295093 hasRelatedWork W2883173479 @default.
- W4286295093 hasRelatedWork W2894999217 @default.
- W4286295093 hasRelatedWork W2896141954 @default.
- W4286295093 hasRelatedWork W2946603276 @default.
- W4286295093 hasRelatedWork W3004910654 @default.
- W4286295093 hasRelatedWork W3086240832 @default.
- W4286295093 hasRelatedWork W4293214253 @default.
- W4286295093 hasRelatedWork W4312462089 @default.
- W4286295093 hasRelatedWork W4312728888 @default.
- W4286295093 hasVolume "40" @default.
- W4286295093 isParatext "false" @default.
- W4286295093 isRetracted "false" @default.
- W4286295093 workType "article" @default.